BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//HCP Ed-UK - ECPv6.15.14//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://hcp-ed.co.uk
X-WR-CALDESC:Events for HCP Ed-UK
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:UTC
BEGIN:STANDARD
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
TZNAME:UTC
DTSTART:20250101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=UTC:20260312T124500
DTEND;TZID=UTC:20260312T140000
DTSTAMP:20260412T014941
CREATED:20260209T204837Z
LAST-MODIFIED:20260313T094806Z
UID:10001477-1773319500-1773324000@hcp-ed.co.uk
SUMMARY:SGLT2 Inhibitors: Beyond Glycaemic Control
DESCRIPTION:Beyond HbA1c: Modern Diabetes Care in Primary Care Nursing \n\n\n\nThe first in a series of three one-hour Lunch & Learn sessions designed for nurses working in general practice\, focusing on contemporary diabetes care beyond glycaemic control. \n\n\n\nSession 1 SGLT2 Inhibitors: Beyond Glycaemic Control \n\n\n\nSession overview/content:This session explores the role of SGLT2 inhibitors in modern diabetes care\, with a particularfocus on their cardiovascular and renal benefits. It will move beyond glucose lowering to helpnurses understand why these medications are increasingly used in people with type 2 diabeteswho have\, or are at risk of\, heart failure and chronic kidney disease. Practical nursingconsiderations\, monitoring\, and patient conversations will be highlighted throughout. \n\n\n\nAim:To enable primary care nurses to understand the non-glycaemic benefits of SGLT2 inhibitorsand their role in improving cardiovascular and renal outcomes in people with type 2 diabetes. \n\n\n\nLearning objectives: \n\n\n\n\nUnderstand key nursing considerations\, including side effects\, sick day rules\, and\n\n\n\npatient counselling\n\n\n\nBy the end of this session\, participants will be able to:\n\n\n\nDescribe how SGLT2 inhibitors work beyond glucose lowering\n\n\n\nExplain the cardiovascular benefits of SGLT2 inhibitors\, particularly in heart failure\n\n\n\nRecognise the renal protective effects of SGLT2 inhibitors in people with type 2\n\n\n\ndiabetes\n\n\n\nIdentify which patients in primary care are most likely to benefit from SGLT2 inhibitor\n\n\n\ntherapy\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\nSpeaker: Tracy Kirk – Director of Education at the Primary Care Respiratory Training Centre.
URL:https://hcp-ed.co.uk/event/sglt2-inhibitors-beyond-glycaemic-control/
LOCATION:Online Webinar
CATEGORIES:Diabetes,Live Presentation
ATTACH;FMTTYPE=image/png:https://hcp-ed.co.uk/wp-content/uploads/2026/02/SGLT2-Inhibitors-Beyond-Glycaemic-Control-1-1.png
END:VEVENT
END:VCALENDAR